Skip to main content
Top
Published in: BMC Psychiatry 1/2016

Open Access 01-12-2016 | Research article

Association between non-compliance with psychiatric treatment and non-psychiatric service utilization and costs in patients with schizophrenia and related disorders

Authors: Soohyun Joe, Jung Sun Lee

Published in: BMC Psychiatry | Issue 1/2016

Login to get access

Abstract

Background

The relationship between medication non-compliance in patients with schizophrenia and related disorders, and increased psychiatric service utilization and costs are well documented; however, non-psychiatric service utilization and costs are not. Therefore, we investigated the association of non-compliance with psychiatric treatment and the utilization and costs of non-psychiatric services.

Methods

Data on South Korean individuals with a lifetime diagnosis of schizophrenia or a related disorder, who were treated in a psychiatric clinic at least twice during 2011, were selected among national data collected for the Health Insurance Review and Assessment Service-National Patients Sample between January 1, 2011 and December 31, 2011. The sample was divided into two overlapping groups with two different classifications of patterns of medication prescription refills: (1) adherent versus non-adherent group, and (2) persistent versus non-persistent group. A matching method was used to remove the effects of different follow-up durations and insurance system on medical service utilization and costs. The final sample for analysis consisted of data from 5,548 individuals in the adherent versus non-adherent group and 3,912 in the persistent versus non-persistent group. Comparisons of the psychiatric and non-psychiatric service utilizations were made between the groups.

Results

The number of psychiatric service utilizations were significantly lower in the non-adherent than the adherent group. They were also significantly lower in the non-persistent group than the persistent group. The number of non-psychiatric service utilizations was significantly higher in the non-adherent group. They were also significantly higher in the non-persistent group than the persistent group. All psychiatric costs per person during the study period were lower in the non-adherent than the adherent group, and lower in the non-persistent than the persistent group. All non-psychiatric costs per person were higher in the non-adherent than the adherent group, and higher in the non-persistent than the persistent group.

Conclusion

Non-adherence to psychiatric treatment by patients with schizophrenia and related disorders was associated with higher medical service utilization and increased personal and societal medical costs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886–91.CrossRefPubMed Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886–91.CrossRefPubMed
2.
go back to reference Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692–9.CrossRefPubMed Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692–9.CrossRefPubMed
3.
4.
go back to reference Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.CrossRefPubMedPubMedCentral Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.CrossRefPubMedPubMedCentral
5.
go back to reference Offord S, Lin J, Wong B, Mirski D, Baker RA. Impact of oral antipsychotic medication adherence on healthcare resource utilizationn among schizophrenia patients with Medicare coverage. Community Ment Health J. 2013;49(6):625–9.CrossRefPubMed Offord S, Lin J, Wong B, Mirski D, Baker RA. Impact of oral antipsychotic medication adherence on healthcare resource utilizationn among schizophrenia patients with Medicare coverage. Community Ment Health J. 2013;49(6):625–9.CrossRefPubMed
6.
go back to reference Tunis S. The impact of schizophrenic patient functionality on service utilization and cost. Am J Manag Care. 1999;5(10 Suppl):S583–90. Tunis S. The impact of schizophrenic patient functionality on service utilization and cost. Am J Manag Care. 1999;5(10 Suppl):S583–90.
7.
go back to reference Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–60.CrossRefPubMed Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–60.CrossRefPubMed
8.
go back to reference Hofer A, Rettenbacher MA, Widschwendter CG, Kemmler G, Hummer M, Fleischhacker WW. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci. 2006;256(4):246–55.CrossRefPubMed Hofer A, Rettenbacher MA, Widschwendter CG, Kemmler G, Hummer M, Fleischhacker WW. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci. 2006;256(4):246–55.CrossRefPubMed
9.
go back to reference Berger A, Edelsberg J, Sanders KN, Alvir JM, Mychaskiw MA, Oster G. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. BMC Psychiatry. 2012;12:99.CrossRefPubMedPubMedCentral Berger A, Edelsberg J, Sanders KN, Alvir JM, Mychaskiw MA, Oster G. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study. BMC Psychiatry. 2012;12:99.CrossRefPubMedPubMedCentral
10.
go back to reference Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry. 2013;13:246.CrossRefPubMedPubMedCentral Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry. 2013;13:246.CrossRefPubMedPubMedCentral
11.
go back to reference Remington G, Khramov I. Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry. 2001;25(2):363–9.CrossRef Remington G, Khramov I. Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry. 2001;25(2):363–9.CrossRef
12.
go back to reference Shi L, Zhao Y, Fonseca V, Ascher-Svanum H, Chiang YJ, Winstead D. Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndrome. Curr Med Res Opin. 2010;26(10):2499–506.CrossRefPubMed Shi L, Zhao Y, Fonseca V, Ascher-Svanum H, Chiang YJ, Winstead D. Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndrome. Curr Med Res Opin. 2010;26(10):2499–506.CrossRefPubMed
13.
go back to reference King D, Knapp M, Patel A, Amaddeo F, Tansella M, Schene A, et al. The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study. Epidemiol Psychiatr Sci. 2014;23(1):61–70.CrossRefPubMed King D, Knapp M, Patel A, Amaddeo F, Tansella M, Schene A, et al. The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study. Epidemiol Psychiatr Sci. 2014;23(1):61–70.CrossRefPubMed
14.
go back to reference Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184:509–16.CrossRefPubMed Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184:509–16.CrossRefPubMed
15.
go back to reference Noordsy DL, Phillips GA, Ball DE, Linde-Zwirble WT. Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. Patient Preference Adherence. 2010;4:263–71.CrossRefPubMedPubMedCentral Noordsy DL, Phillips GA, Ball DE, Linde-Zwirble WT. Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. Patient Preference Adherence. 2010;4:263–71.CrossRefPubMedPubMedCentral
16.
go back to reference Statistics Korea. The Sixth Revision of the Korean Standard Classification of Diseases. Seoul: Statistics Korea; 2010. Statistics Korea. The Sixth Revision of the Korean Standard Classification of Diseases. Seoul: Statistics Korea; 2010.
18.
go back to reference Cramer J, Roy A, Burrel A, Fairchild C, Fuldeore M, Ollendorf D, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.CrossRefPubMed Cramer J, Roy A, Burrel A, Fairchild C, Fuldeore M, Ollendorf D, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.CrossRefPubMed
19.
go back to reference Yeaw J, Benner J, Walt J, Sian S, Smith D. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–40.PubMed Yeaw J, Benner J, Walt J, Sian S, Smith D. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–40.PubMed
20.
go back to reference American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry. 1997;154(4 Suppl): 1–63. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry. 1997;154(4 Suppl): 1–63.
21.
go back to reference Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111–7.CrossRefPubMed Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111–7.CrossRefPubMed
22.
go back to reference Nayak RK, Doose DR, Nair NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol. 1987;27(2):144–50.CrossRefPubMed Nayak RK, Doose DR, Nair NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol. 1987;27(2):144–50.CrossRefPubMed
23.
go back to reference Schooler NR, Levine J. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmakopsychiatr Neuropsychopharmakol. 1976;9(4):159–69.PubMed Schooler NR, Levine J. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmakopsychiatr Neuropsychopharmakol. 1976;9(4):159–69.PubMed
24.
go back to reference Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–7.CrossRefPubMed Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–7.CrossRefPubMed
25.
go back to reference Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997;28(2–3):199–206.CrossRefPubMed Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997;28(2–3):199–206.CrossRefPubMed
26.
go back to reference Hall RC, Gardner ER, Popkin MK, Lecann AF, Stickney SK. Unrecognized physical illness prompting psychiatric admission: a prospective study. Am J Psychiatry. 1981;138(5):629–35.CrossRefPubMed Hall RC, Gardner ER, Popkin MK, Lecann AF, Stickney SK. Unrecognized physical illness prompting psychiatric admission: a prospective study. Am J Psychiatry. 1981;138(5):629–35.CrossRefPubMed
27.
go back to reference Koran LM, Sox Jr HC, Marton KI, Moltzen S, Sox CH, Kraemer HC, et al. Medical evaluation of psychiatric patients. I. Results in a state mental health system. Arch Gen Psychiatry. 1989;46(8):733–40.CrossRefPubMed Koran LM, Sox Jr HC, Marton KI, Moltzen S, Sox CH, Kraemer HC, et al. Medical evaluation of psychiatric patients. I. Results in a state mental health system. Arch Gen Psychiatry. 1989;46(8):733–40.CrossRefPubMed
28.
go back to reference Koranyi EK. Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population. Arch Gen Psychiatry. 1979;36(4):414–9.CrossRefPubMed Koranyi EK. Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population. Arch Gen Psychiatry. 1979;36(4):414–9.CrossRefPubMed
29.
go back to reference Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust. 2003;178(Suppl):S67–70.PubMed Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust. 2003;178(Suppl):S67–70.PubMed
30.
go back to reference Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med. 2006;21(11):1133–7.CrossRefPubMedPubMedCentral Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med. 2006;21(11):1133–7.CrossRefPubMedPubMedCentral
Metadata
Title
Association between non-compliance with psychiatric treatment and non-psychiatric service utilization and costs in patients with schizophrenia and related disorders
Authors
Soohyun Joe
Jung Sun Lee
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2016
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-016-1156-3

Other articles of this Issue 1/2016

BMC Psychiatry 1/2016 Go to the issue